NYSE:PRGOPharmaceuticals
Assessing Perrigo (PRGO) Valuation After Impairment-Driven Loss And Weaker Full-Year Sales Outlook
Perrigo (PRGO) stock is in focus after the company reported a sharply higher first quarter net loss, driven by a US$330.8 million goodwill impairment charge, and reaffirmed guidance for full year net sales to decline.
See our latest analysis for Perrigo.
The earnings miss, goodwill impairment and reaffirmed outlook for lower net sales have coincided with clear selling pressure, with the share price down 10.1% over the past month and the 1 year total shareholder return declining 58.6%,...